Trials / Unknown
UnknownNCT01534442
Atropin and Glucose Stimulated Insulinsecretion and the Cephalic Insulin Response
The Significances of Atropin Administration for the GLP-1 Potentiation of Glucose Induced Insulin Secretion and the Cephalic Insulin Response
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- University Hospital, Gentofte, Copenhagen · Academic / Other
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to investigate the role of transmission of vagal cholinerg for the GLP-1 potentiation of the glucose stimulated insulin secretion and the cephalic insulin response by using atropin administration. The hypothesis is that a great deal of the effects of GLP-1 is mediated via the nervous system and for this reason the investigators will research individuals with an intact nervous supply with and without atropin administration.
Detailed description
GLP-1 is a importent enterogastron and incretin hormone. Rapid degradation of GLP-1 by dipeptidyl peptidase 4 (DPP-4) suggests that GLP-1 may act locally (through vagal afferents) before being degraded. We aimed to clarify the role of vagal innervation on the incretin effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atropine | 1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts. |
| DRUG | Placebo |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2012-02-16
- Last updated
- 2012-12-07
Locations
2 sites across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01534442. Inclusion in this directory is not an endorsement.